Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma Full Text
Cancer, 07/01/2011
Clinical Article
Edeline J et al.– The current series validated modified response evaluation criteria in solid tumors (mRECIST) in patients who received sorafenib (Sor) for advanced hepatocellular carcinoma (HCC). The majority of patients who had SD according to RECIST had a different prognosis according to mRECIST. The results indicated that, for patients with HCC, mRECIST should be used for the standard assessment of treatment efficacy, particularly in patients who are receiving antiangiogenic drugs.



